New ALS drug candidate QRL-101 tested in small safety trial
NCT ID NCT06714396
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 1 study tested a single dose of the experimental drug QRL-101 in 12 people with ALS. The main goals were to see how the drug moves through the body and whether it is safe. Participants received either QRL-101 or a placebo, and researchers monitored side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QRL-101
- What this could lead to
- If this early study shows QRL-101 is safe and well-tolerated, it could support larger trials to see if it helps control ALS progression.
- What could go wrong
- This is a very small, early-phase trial with only 12 participants. It is designed mainly to check safety and drug levels, not to prove the drug works for ALS. Many drugs fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- Can a cancer drug slow ALS? a trial aims to find out
- Can conversation unlock clues to ALS speech decline?
- Could a simple Pre-Tube ritual ease feeding problems in ALS?
- Can tracking brain changes over time unlock the secrets of frontotemporal dementia?
- A muscle test in the thigh may reveal how ALS attacks the body